Blog From Niche to Necessity: Precision Medicine Isn’t an Initiative. It’s the New Infrastructure.By James Lu, MD, PhD, CEO and Co-Founder of Helix
Press ReleasesHelix GenoSphere™ Launches MASH-Enriched Cohort of Over 17,000 Linked Clinico-Genomic Records to Accelerate Drug Discovery and DevelopmentOctober 15, 2025
Press ReleasesHelix to Present New Population-Scale Genomic Research at ASHG 2025 Annual MeetingOctober 7, 2025
VideosPartner Perspectives with Nebraska MedicineGenetic Insights Project helps Nebraskans take charge of their health
1Published ResearchFrom Uncertain to Actionable: Significant Reduction in Variants of Uncertain Significance in Hereditary Germline Testing via Multi-Institutional Real-World EvidenceAugust 15, 2025
2Published ResearchNovel Method for Predicting Lp(a) From Genomic Testing Identifies ASCVD Risk Across a Diverse CohortJuly 30, 2025
3Published ResearchChatbot for the Return of Positive Genetic Screening Results for Hereditary Cancer Syndromes: Prompt Engineering ProjectJune 10, 2025
4Published ResearchIndividuals with PMS2 pathogenic variants are at average risk of cancer before age 60March 19, 2025
5Published ResearchScalable system-wide CYP2C19 pharmacogenomic testing reveals 38% excess incidence of adverse events in metabolizers receiving inappropriate prescriptionsMarch 19, 2025
Blog From Niche to Necessity: Precision Medicine Isn’t an Initiative. It’s the New Infrastructure.By James Lu, MD, PhD, CEO and Co-Founder of Helix
Press ReleasesHelix GenoSphere™ Launches MASH-Enriched Cohort of Over 17,000 Linked Clinico-Genomic Records to Accelerate Drug Discovery and DevelopmentOctober 15, 2025
Press ReleasesHelix to Present New Population-Scale Genomic Research at ASHG 2025 Annual MeetingOctober 7, 2025
VideosPartner Perspectives with Nebraska MedicineGenetic Insights Project helps Nebraskans take charge of their health
1Published ResearchFrom Uncertain to Actionable: Significant Reduction in Variants of Uncertain Significance in Hereditary Germline Testing via Multi-Institutional Real-World EvidenceAugust 15, 2025
2Published ResearchNovel Method for Predicting Lp(a) From Genomic Testing Identifies ASCVD Risk Across a Diverse CohortJuly 30, 2025
3Published ResearchChatbot for the Return of Positive Genetic Screening Results for Hereditary Cancer Syndromes: Prompt Engineering ProjectJune 10, 2025
4Published ResearchIndividuals with PMS2 pathogenic variants are at average risk of cancer before age 60March 19, 2025
5Published ResearchScalable system-wide CYP2C19 pharmacogenomic testing reveals 38% excess incidence of adverse events in metabolizers receiving inappropriate prescriptionsMarch 19, 2025
Press ReleasesFeb 3, 2025Helix Launches World's Largest Clinico-Genomic Cohort of GLP-1 Agonist Treated Patients
Press ReleasesJan 15, 2025The Helix Research Network Adds Three New Health System Members, Transforming Clinical Genomics for Community Benefit
Press ReleasesJan 13, 2025Helix Partners with Komodo Health, Combining Helix's Clinico-Genomic Datasets with Komodo's Healthcare Map® for Clinical & Research Impact
ResearchNov 21, 2024Underestimated risk of secondary complications in pathogenic and glucose-elevating GCK variant carriers with type 2 diabetes
Press ReleasesNov 13, 2024Helix Debuts Novel Precision Effectiveness Model That Predicts 12-Month Weight Loss Response of Semaglutide in Diverse Populations
ResearchNov 4, 2024A novel method for predicting Lp(a) levels from routine outpatient genomic testing identifies those at risk of cardiovascular disease across a diverse cohort